4.5 Article

In vitro enantioselective inhibition of the main human CYP450 enzymes involved in drug metabolism by the chiral pesticide tebuconazole

期刊

TOXICOLOGY LETTERS
卷 351, 期 -, 页码 1-9

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.toxlet.2021.08.006

关键词

Tebuconazole; Chiral; Cytochrome P450; Inhibition; Human liver microsomes; Enantioselective

资金

  1. Sao Paulo Research Foundation (FAPESP) [2014/50945-4, 2017/03204-7, 2018/07534-4]
  2. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq - INCT-DATREM) [465571/2014-0]
  3. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) [001]

向作者/读者索取更多资源

The study investigated the inhibitory potential of the fungicide Tebuconazole on human liver microsomes and found that it may potentially cause pesticide-drug interactions by inhibiting CYP450 enzymes.
Tebuconazole (TEB) is a chiral triazole fungicide worldwide employed to control plant pathogens and preserve wood. People can be exposed to TEB either through diet and occupational contamination. This work investigates the in vitro inhibitory potential of rac-TEB, S-(+)-TEB, and R-(-)-TEB over the main cytochrome P450 enzymes (CYP450) using human liver microsomes to predict TEB in vivo inhibition potential. The IC50 values showed that in vitro inhibition was enantioselective for CYP2C9, CYP2C19, and CYP2D6, but not for CYP3A4/5. Despite enantioselectivity, rac-TEB and its single enantiomers were always classified in the same category. The inhibition mechanisms and constants were determined for rac-TEB and it has shown to be a mixed inhibitor of CYP3A4/5 (K-i = 1.3 +/- 0.3 mu M, alpha K-i = 3.2 +/- 0.5 mu M; K-i = 0.6 +/- 0.3 mu M, alpha K-i = 1.3 +/- 0.3 mu M) and CYP2C9 (K-i = 0.7 +/- 0.1 mu M, alpha K-i = 2.7 +/- 0.5 mu M), and a competitive inhibitor of CYP2D6 (K-i = 11.9 +/- 0.7 mu M) and CYP2C19 (K-i = 0.23 +/- 0.02 mu M), respectively, suggesting that in some cases, rac-TEB has a higher or comparable inhibitory potential than well-known strong inhibitors of CYP450 enzymes, especially for CYP2C9 and CYP2C19. In vitro-in vivo extrapolations (IVIVE) were conducted based on the results and data available in the literature about TEB absorption and metabolism. R1 values were estimated based on the Food and Drug Administration guideline and suggested that in a chronic oral exposure scenario considering the acceptable daily intake dose proposed by the European Food and Safety Authority, the hypothesis of rac-TEB to inhibit the activities of CYP3A4/5, CYP2C9, and CYP2C19 in vivo and cause pesticide-drug interactions cannot be disregarded. 2021 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据